University of Minnesota

The University of North Carolina at Chapel Hill

St. Jude Children's Research Hospital

Albert-ludwigs-universitat Freiburg

Albert-ludwigs-universitaet Freiburg

Jeff S Miller

Bruce Robert Blazar

Robert Zeiser

Peter J Murray

Brent Koehn

Jenny P Y Ting

Michael Verneris

Yong-Oon Ahn

Brent H Koehn

In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells

The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.

Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells

Growing community of inventors

Little Canada, MN, United States of America

Jeff S Miller